Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TEQUILLA COMPANY PRYOR

Allopathic & Osteopathic Physicians Pediatrics

NPI
1568807741
CMS profile
1569036
Location
FAYETTEVILLE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,119.16

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $731.53 3
Food and Beverage $387.63 6

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $1,102.29 8
SANOFI PASTEUR INC. $16.87 1

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TEQUILLA COMPANY PRYOR

NPI 1568807741 · CMS profile ID 1569036

Allopathic & Osteopathic Physicians / Pediatrics

FAYETTEVILLE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568807741?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TEQUILLA COMPANY PRYOR, NPI 1568807741, CMS profile ID 1569036. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568807741?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). TEQUILLA COMPANY PRYOR, NPI 1568807741, CMS profile ID 1569036. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568807741?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
TEQUILLA COMPANY PRYOR, NPI 1568807741, CMS profile ID 1569036, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1568807741?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $1,119.16 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $43.6511/07/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155834192 CMS
AstraZeneca Pharmaceuticals LP $54.9911/07/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155835204 CMS
AstraZeneca Pharmaceuticals LP $46.4011/07/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155836512 CMS
AstraZeneca Pharmaceuticals LP $221.7011/07/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155836752 CMS
AstraZeneca Pharmaceuticals LP $320.0411/07/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155837672 CMS
AstraZeneca Pharmaceuticals LP $189.7911/07/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155840512 CMS
AstraZeneca Pharmaceuticals LP $123.9911/07/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155840644 CMS
AstraZeneca Pharmaceuticals LP $101.7311/07/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155841148 CMS
SANOFI PASTEUR INC. $16.8709/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128748065 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2024 $1,119.16 9

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,763.18 10
PY2025 Principal investigator $147,853.28 28
PY2024 Recipient $475.81 6
PY2024 Principal investigator $71,235.42 14
PY2023 Principal investigator $5,924.00 3
PY2022 Principal investigator $913.00 1
PY2021 Principal investigator $18,436.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI PASTEUR INC. $2,138.40 12/19/2025 Non-covered Recipient Entity
Javara Inc
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226103781
Principal investigator 1 PFIZER INC. $405.41 12/10/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228719400
Principal investigator 1 SANOFI PASTEUR INC. $1,069.20 12/01/2025 Non-covered Recipient Entity
Javara Inc
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226103770
Principal investigator 1 SANOFI PASTEUR INC. $5,000.00 11/12/2025 Non-covered Recipient Entity
Javara Inc
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226103787
Principal investigator 1 PFIZER INC. $405.41 10/22/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228740314
Principal investigator 1 GlaxoSmithKline, LLC. $9,898.00 10/10/2025 Non-covered Recipient Entity
JAVARA INC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO DEMONSTRAT No dispute reported 06/30/2026 1192162927
Principal investigator 1 GlaxoSmithKline, LLC. $16,500.00 10/10/2025 Non-covered Recipient Entity
JAVARA INC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO DEMONSTRAT No dispute reported 06/30/2026 1192162931
Principal investigator 1 GlaxoSmithKline, LLC. $4,000.00 10/10/2025 Non-covered Recipient Entity
JAVARA INC
A PHASE 3A, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO DEMONSTRAT No dispute reported 06/30/2026 1192166310
Principal investigator 1 PFIZER INC. $5,495.85 09/10/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228752461
Principal investigator 1 ModernaTX, Inc. $787.00 08/06/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252974047
Principal investigator 1 ModernaTX, Inc. $1,763.00 08/06/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252974049
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/06/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252974051
Principal investigator 1 ModernaTX, Inc. $2,000.00 08/06/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252974053
Principal investigator 1 ModernaTX, Inc. $1,050.00 08/06/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252974055
Principal investigator 1 ModernaTX, Inc. $1,900.00 08/06/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252974057
Principal investigator 1 ModernaTX, Inc. $1,218.00 08/06/2025 Non-covered Recipient Entity
JAVARA INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252974059
Principal investigator 1 SANOFI PASTEUR INC. $1,108.35 08/01/2025 Non-covered Recipient Entity
Javara Inc
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226103758
Principal investigator 1 PFIZER INC. $1,443.02 07/30/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228783721
Principal investigator 1 PFIZER INC. $2,800.00 07/23/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228782934
Principal investigator 1 PFIZER INC. $5,217.10 07/01/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228764827
Recipient SANOFI PASTEUR INC. $16.00 06/12/2025 Covered Recipient Physician A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226106134
Recipient SANOFI PASTEUR INC. $42.55 06/12/2025 Covered Recipient Physician A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226106140
Recipient SANOFI PASTEUR INC. $107.84 06/12/2025 Covered Recipient Physician A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226106149
Recipient SANOFI PASTEUR INC. $107.84 06/12/2025 Covered Recipient Physician A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226106155
Recipient SANOFI PASTEUR INC. $568.55 06/12/2025 Covered Recipient Physician A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226106159
Recipient SANOFI PASTEUR INC. $371.77 06/12/2025 Covered Recipient Physician A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226106165
Recipient SANOFI PASTEUR INC. $189.00 06/12/2025 Covered Recipient Physician A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226106170
Recipient SANOFI PASTEUR INC. $110.89 06/12/2025 Covered Recipient Physician A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226106176
Recipient SANOFI PASTEUR INC. $124.37 06/12/2025 Covered Recipient Physician A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226106180
Recipient SANOFI PASTEUR INC. $124.37 06/12/2025 Covered Recipient Physician A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226106185
Principal investigator 1 SANOFI PASTEUR INC. $12,721.05 06/06/2025 Non-covered Recipient Entity
Javara Inc
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226103726
Principal investigator 1 PFIZER INC. $1,443.02 06/04/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228774305
Principal investigator 1 PFIZER INC. $7,951.78 05/30/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228772426
Principal investigator 1 AstraZeneca UK Limited $27,781.45 04/28/2025 Non-covered Recipient Entity
JAVARA, INC
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185548681
Principal investigator 1 SANOFI PASTEUR INC. $12,500.00 04/25/2025 Non-covered Recipient Entity
Javara Inc
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226103720
Principal investigator 1 SANOFI PASTEUR INC. $12,200.00 04/11/2025 Non-covered Recipient Entity
Javara Inc
A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenicity of Catch-up Vaccination Regimens of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children, and Adolescents No dispute reported 06/30/2026 1226103713
Principal investigator 1 PFIZER INC. $3,403.62 03/19/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228798003
Principal investigator 1 PFIZER INC. $4,153.62 03/18/2025 Non-covered Recipient Entity
Javara Inc
A PHASE 2 RANDOMIZED PARTIALLY DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE No dispute reported 06/30/2026 1228794778